Search hospitals > California > San Marcos
Kaiser Permanente-San Marcos
Claim this profileSan Marcos, California 92078
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast cancer
Conducts research for Cancer
125 reported clinical trials
8 medical researchers
Summary
Kaiser Permanente-San Marcos is a medical facility located in San Marcos, California. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Breast cancer, Cancer and other specialties. Kaiser Permanente-San Marcos is involved with conducting 125 clinical trials across 295 conditions. There are 8 research doctors associated with this hospital, such as Gary L. Buchschacher, Helen H. Moon, Ashraf R. Aziz, and Eric C. McGary.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage II
Stage I
2Breast Cancer
Global LeaderHER2 negative
Stage IV
ER positive
Top PIs
Gary L. BuchschacherKaiser Permanente-Anaheim8 years of reported clinical research
Studies Colon Cancer
Studies Colorectal Cancer
14 reported clinical trials
34 drugs studied
Helen H. MoonKaiser Permanente-Riverside8 years of reported clinical research
Studies Kidney Cancer
Studies Bladder Cancer
13 reported clinical trials
23 drugs studied
Ashraf R. AzizKaiser Permanente-Baldwin Park6 years of reported clinical research
Studies Multiple Myeloma
Studies Lymphoma
11 reported clinical trials
31 drugs studied
Eric C. McGaryKaiser Permanente-Anaheim11 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
11 reported clinical trials
19 drugs studied
Clinical Trials running at Kaiser Permanente-San Marcos
Lung Cancer
Breast Cancer
Ovarian Cancer
Bladder Cancer
Breast cancer
Non-Small Cell Lung Cancer
Esophageal cancer
Prostate Cancer
Colon Cancer
Cancer
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Tepotinib + Ramucirumab
for Lung Cancer
This phase II Expanded Lung-MAP treatment trial tests tepotinib with or without ramucirumab for the treatment of patients with advanced non-small cell lung cancer that has spread from where it first started (primary site) to other places in the body (stage IV) or that has come back after a period of improvement (recurrent). Tepotinib is used in patients whose cancer has a mutated (changed) form of a gene called MET. It is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal MET protein that signals tumor cells to multiply. This helps slow or stop the spread of tumor cells. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Giving tepotinib with ramucirumab may lower the chance of the cancer from growing or spreading in patients with stage IV or recurrent non-small cell lung cancer.
Recruiting1 award Phase 24 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Kaiser Permanente-San Marcos?
Kaiser Permanente-San Marcos is a medical facility located in San Marcos, California. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Breast cancer, Cancer and other specialties. Kaiser Permanente-San Marcos is involved with conducting 125 clinical trials across 295 conditions. There are 8 research doctors associated with this hospital, such as Gary L. Buchschacher, Helen H. Moon, Ashraf R. Aziz, and Eric C. McGary.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.